Avalo Therapeutics, Inc. (AVTX) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 3 Buy, 1 Hold, 1 Sell.
The consensus price target is $44.50 (low: $39.00, high: $50.00), representing an upside of 220.1% from the current price $13.90.
Analysts estimate Earnings Per Share (EPS) of $-18.45 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.32 vs est $-18.45 (beat +76.6%). 2025: actual $-5.84 vs est $-6.71 (beat +13%). Analyst accuracy: 0%.
AVTX Stock — 12-Month Price Forecast
$44.50
▲ +220.14% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Avalo Therapeutics, Inc., the average price target is $44.50, with a high forecast of $50.00, and a low forecast of $39.00.
The average price target represents a +220.14% change from the last price of $13.90.
Highest Price Target
$50.00
Average Price Target
$44.50
Lowest Price Target
$39.00
AVTX Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to Avalo Therapeutics, Inc. in the past 3 months
EPS Estimates — AVTX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$4.32
vs Est –$18.45
▲ 327.0% off
2025
Actual –$5.84
vs Est –$6.71
▲ 14.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — AVTX
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 58.5% off
2025
Actual $0.000B
vs Est $0.001B
▼ 1,594.9% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
